Exelixis (LTS:0IJO) Accounts Payable : $38 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Exelixis Accounts Payable?

Exelixis's Accounts Payable for the quarter that ended in Dec. 2024 was $38 Mil.

Exelixis's quarterly Accounts Payable increased from Jun. 2024 ($29 Mil) to Sep. 2024 ($59 Mil) but then declined from Sep. 2024 ($59 Mil) to Dec. 2024 ($38 Mil).

Exelixis's annual Accounts Payable increased from Dec. 2022 ($33 Mil) to Dec. 2023 ($34 Mil) and increased from Dec. 2023 ($34 Mil) to Dec. 2024 ($38 Mil).

Exelixis Accounts Payable Historical Data

The historical data trend for Exelixis's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exelixis Accounts Payable Chart

Exelixis Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable

Get a 7-Day Free Trial

23.63

24.26

32.67

33.77

38.19

Exelixis Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Accounts Payable	Get a 7-Day Free Trial															33.77	26.07	28.68	59.31	38.19

Exelixis Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Exelixis Accounts Payable Related Terms

Thank you for viewing the detailed overview of Exelixis's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Exelixis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (LTS:0IJO) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

EXEL:USA EX9:Germany EX9:Germany

Address

1851 Harbor Bay Parkway, Alameda, CA, USA, 94502

Website

https://www.exelixis.com

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Exelixis Headlines

No Headlines